Postmarketing data about the effectiveness of zonisamide in childhood epilepsy was collected from 759 children with various forms of epilepsy (ages 3 months-15 years) to compare the long-term efficacy of zonisamide in the treatment of epilepsy in intellectually normal versus intellectually disabled children. The follow-up period was 6 months-3 years; 291 children (245 intellectually normal, 46 ...

PURPOSE Zonisamide is licensed for adjunctive therapy for partial-onset seizures with or without secondary generalisation in patients 6 years and older and as monotherapy for the treatment of partial seizures in adult patients with newly diagnosed epilepsy, and shows a favourable pharmacokinetic profile with low interaction potential with other drugs. The aim of the present study was to gather ...

OBJECTIVE The pharmacological therapy for essential tremor (ET) is inadequate, and many patients resort to surgical procedures. Zonisamide is an antiepileptic with several potential mechanisms of action. MATERIALS AND METHODS We evaluated zonisamide for ET in an open-label pilot trial. The primary efficacy point was the change in the Tremor Study Group rating scale (TSGRS) scores. RESULTS T...

Zonisamide is an antiepileptic drug that is structurally different from other antiepileptic agents. Its long half-life, once-daily dosing, lack of induction of hepatic enzymes, and broad spectrum of action makes it a suitable candidate for monotherapy. It has been approved as monotherapy for partial onset epilepsy in Japan and South Korea for more than a decade, and was recently approved as mon...

In the past twenty years, 14 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. In general, the clinical utility of therapeutic drug monitoring has not bee...

Although established antiepilepsy drugs (AEDs) are efficacious and new drugs have become available to treat patients with epilepsy, at least 30% of all patients remain refractory to available treatment.1 Continued efforts to identify and develop new compounds for the treatment of epilepsy motivate all concerned because of the plight of so many patients. In the following sections, data are provi...